Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid

Simone H.J. van den Elsen, Onno W. Akkerman, Mireille Wessels, Erwin M. Jongedijk, Samiksha Ghimire, Tjip S. van der Werf, Mathieu S. Bolhuis, Daan J. Touw, Jan‐Willem C. Alffenaar

European Respiratory Journal · 2020 · 10 citations · 9 references

DOIFull text

Open access

Concepts

Abstract

<b>Therapeutic drug monitoring using saliva samples is feasible for rifampicin, despite low penetration, but is not feasible for isoniazid, which showed inexplicable highly variable saliva/serum concentration ratios</b>https://bit.ly/2yAS2Jc

References

9